세계의 인간 생식기술 시장 : 유형, 용도, 최종 사용자별 예측(2025-2030년)

The Human Reproductive Technologies Market was valued at USD 29.84 billion in 2023, expected to reach USD 31.82 billion in 2024, and is projected to grow at a CAGR of 6.66%, to USD 46.89 billion by 2030.

Human Reproductive Technologies are a diverse set of treatments and technologies aimed at assisting human reproduction through medical and scientific interventions. This scope includes in vitro fertilization (IVF), artificial insemination, fertility drugs, surrogacy, and emerging genomics technologies. The necessity for these technologies is primarily driven by the increasing prevalence of infertility due to delayed childbearing, lifestyle factors, and certain medical conditions. Application-wise, they are extensively utilized in fertility clinics, hospitals, and healthcare research institutions. End-use spans across individual couples desiring children, same-sex couples, and single parents seeking reproductive assistance.

The market is significantly influenced by the growing awareness and acceptance of reproductive health technologies, advancements in medical sciences, and supportive government regulations for fertility tourism. Moreover, rising disposable income and better healthcare infrastructure in emerging economies drive demand. However, the market faces limitations such as high costs of treatment, ethical and legal concerns, and the potential for psychological stress among patients. Challenges include societal stigmas and varied legal frameworks across different regions impacting technology adoption.

Potential growth opportunities lie in developing affordable and accessible treatment options, personalized medicine adapting reproductive technologies to individual genetic profiles, and advancing technologies such as artificial intelligence to predict treatment outcomes effectively. For businesses looking to capitalize on these opportunities, investment in research and development to create innovative fertility solutions, forming partnerships with healthcare providers for wider service distribution, and advocating for policies that support accessibility and insurance coverage can be strategic steps. Innovation hotspots include non-invasive fertility diagnostics, embryo and gamete cryopreservation, and mobile health applications for patient engagement and education. The market is characterized by rapid technological advancements, increasing competition, and potential collaboration between biotechnology firms, pharmaceuticals, and healthcare sectors to address unmet needs effectively while navigating ethical and regulatory landscapes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Reproductive Technologies Market

The Human Reproductive Technologies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Changing lifestyles and rising prevalence of infertility and fertility-related disorders
  • Growing medical tourism for specialized fertility treatments
  • Increasing awareness and acceptance of fertility treatments
• Market Restraints
  • High cost and limited insurance coverage for fertility treatments
• Market Opportunities
  • Advancements and innovations in human reproductive technology for more effective treatment
  • Patents and copyrights for innovations in the reproductive technologies
• Market Challenges
  • Limited success rates and associated health risks

Porter's Five Forces: A Strategic Tool for Navigating the Human Reproductive Technologies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Reproductive Technologies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Reproductive Technologies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Reproductive Technologies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Reproductive Technologies Market

A detailed market share analysis in the Human Reproductive Technologies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Reproductive Technologies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Reproductive Technologies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Reproductive Technologies Market

A strategic analysis of the Human Reproductive Technologies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Reproductive Technologies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Aurobindo Pharma, Bayer AG, CooperSurgical Fertility Solutions, Eli Lilly and Company, European Sperm Bank, Evofem Biosciences, Inc., Ferring B.V., GSK PLC, InSEM Fertility Solutions, INVO Bioscience, KG Medical Industries, Mankind Pharma, Merck KGaA, Microm UK Ltd., Monash IVF Group, Pfizer Inc., Pride Angel, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., V Conceive, Vitrolab AB, and Voxtur Bio Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Reproductive Technologies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Assisted Reproductive Technology, In Vitro Fertilizartion, Intrauterine Insemination, Preimplantation Genetic Testing, and Surrogacy.
• Based on Application, market is studied across Fertility Preservation, Genetic Screening, and Infertility Treatment.
• Based on End-User, market is studied across Fertility Clinics, Hospitals, and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Changing lifestyles and rising prevalence of infertility and fertility-related disorders
    • 5.1.1.2. Growing medical tourism for specialized fertility treatments
    • 5.1.1.3. Increasing awareness and acceptance of fertility treatments
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and limited insurance coverage for fertility treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements and innovations in human reproductive technology for more effective treatment
    • 5.1.3.2. Patents and copyrights for innovations in the reproductive technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Limited success rates and associated health risks
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Human Reproductive Technologies Market, by Type

• 6.1. Introduction
• 6.2. Assisted Reproductive Technology
• 6.3. In Vitro Fertilizartion
• 6.4. Intrauterine Insemination
• 6.5. Preimplantation Genetic Testing
• 6.6. Surrogacy

7. Human Reproductive Technologies Market, by Application

• 7.1. Introduction
• 7.2. Fertility Preservation
• 7.3. Genetic Screening
• 7.4. Infertility Treatment

8. Human Reproductive Technologies Market, by End-User

• 8.1. Introduction
• 8.2. Fertility Clinics
• 8.3. Hospitals
• 8.4. Research & Academic Institutes

9. Americas Human Reproductive Technologies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Human Reproductive Technologies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Human Reproductive Technologies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Aurobindo Pharma
• 4. Bayer AG
• 5. CooperSurgical Fertility Solutions
• 6. Eli Lilly and Company
• 7. European Sperm Bank
• 8. Evofem Biosciences, Inc.
• 9. Ferring B.V.
• 10. GSK PLC
• 11. InSEM Fertility Solutions
• 12. INVO Bioscience
• 13. KG Medical Industries
• 14. Mankind Pharma
• 15. Merck KGaA
• 16. Microm UK Ltd.
• 17. Monash IVF Group
• 18. Pfizer Inc.
• 19. Pride Angel
• 20. Sandoz International GmbH
• 21. Sun Pharmaceutical Industries Ltd.
• 22. Teva Pharmaceutical Industries Ltd.
• 23. V Conceive
• 24. Vitrolab AB
• 25. Voxtur Bio Ltd.